Global Continuous Glucose Monitoring Market Report by Component (Sensors, Transmitters, Receivers), End-User (Hospitals, Homecare Settings, Others), Regions and Company Analysis 2024-2032

Global Continuous Glucose Monitoring Market Analysis

Global Continuous Glucose Monitoring Market value is forecasted to be around US$ 12.87 Billion by 2032. The CAGR for the market from 2024 to 2032 is 8.22%. Renub Research says that it amounted to US$ 6.32 Billion in 2023.

Continuous glucose monitoring (CGM) is a tool for humans with diabetes. It is a wearable technology that makes it less complicated to detect blood sugar levels through the years. Blood sugar is another term for blood glucose. Monitoring blood glucose levels tells people how much insulin their body needs and when. Blood sugar levels that go up and down a lot can damage the body otherwise. Very excessive (hyperglycemia) or low (hypoglycemia) blood sugar degrees can be dangerous or even life-threatening if not treated quickly. Many things (such as foods eaten, sports activities played, and lifestyle) can affect blood sugar levels. However, diabetes influences everybody differently. Using a CGM tool can simplify controlling Type 1 or Type 2 diabetes. Some patients use CGM for a week to understand their blood sugar patterns. Most use CGM for a lengthy period.

Global Continuous Glucose Monitoring Market Trends

•    Growth in the Prediabetes Prevalence

Prediabetes means a person has a higher than ordinary blood sugar level. It is not always excessive enough to be considered type 2 diabetes yet. However, without lifestyle modifications, adults and kids with prediabetes are at high risk of developing type 2 diabetes. The NIH defined prediabetes through impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). The global occurrence of IFG in 2021 was 5.8% (298 million) and is projected to grow to 6.5% (414 million) in 2045. The 2021 occurrence of IGT and IFG was highest in excessive-profits countries. In 2045, the most considerable relative growth in cases of IGT and IFG would be in low-profit countries. This is predicted to add appreciably to the global continuous glucose monitoring market.

•    Increasing Older Population

Diabetes rates soar even higher at the onset of senior years. Age is a considerable risk element for type 2. The older humans are, the more likely they are to have it. The International Diabetes Federation Diabetes Atlas estimated that 19.3% of individuals aged 65–99 have diabetes. It is projected that the range of humans older than 65 (65–99 years) with diabetes will attain 195.2 Million by 2030 and 276.2 Million by 2045. As people age, they are more likely to have some medical conditions, including high blood pressure and cholesterol. That could make it more difficult for people to keep their diabetes under control. In turn, diabetes can lead to different health problems like heart disorders. So, the growth in the elderly population is anticipated to propel the global continuous glucose monitoring industry.

•    Technological Innovations and Improvements

Diabetes technology like continuous glucose monitoring (CGM) continues to evolve swiftly. CGM gadgets are acquainted with many humans living with diabetes. They are a rapidly changing, innovative section within the diabetes care market. The technology behind those devices has become more accurate and advanced over the last few years, with a couple of primary medical device enterprises entering the global continuous glucose monitoring market. For instance, in February 2024, DexCom launched its real-time CGM device, Dexcom ONE+, in Spain, Belgium, and Poland. The Dexcom ONE+ gadget includes a waterproof sensor to measure blood glucose, a transmitter that sends CGM readings, and a Dexcom One smartphone-compatible app. The machine permits the consumer to monitor blood glucose in real time and ten extra people for shared monitoring. 

United States Continuous Glucose Monitoring Market

The United States is predicted to dominate the global continuous glucose monitoring market. This is because of the increasing incidence of diabetes and the rising adoption of CGM devices. The NIDDK forecasted that 38.4 million people of every age had diabetes (11.6% of the population) in 2021. 38.1 million had been adults ages 18 years or older. Out of U.S. adults aged 18 and older, over one-third, or 97.6 million, had pre-diabetes in 2021. A higher percentage of men (41%) than women (32%) had pre-diabetes in 2017–2020 when data were adjusted by age.

The NCBI article said that nearly 70% of providers recommended CGM use in the majority of their patients with type 1 diabetes. Half of the providers suggested CGM use in 10% to 50% of their patients with type 2 diabetes. All respondents believed CGM advanced the quality of life and would optimize diabetes management.

Government and private sector initiatives for diabetes care are also driving the growth of the global continuous glucose monitoring industry. The Medicare Diabetes Prevention Program (MDPP) and the National Diabetes Prevention Program (National DPP) by the CDC are among the highlights.

Global Continuous Glucose Monitoring Company News

Dexcom Inc., Ypsomed AG, Abbott Laboratories, Senseonics Holdings, Inc., Nemaura Medical, Inc., Medtronic, Inc., Tandem Diabetes Care, and Nova Biomedical are vital businesses in the global continuous monitoring industry.

• In March 2024 - The FDA approved The Dexcom Stelo Glucose Biosensor System for over-the-counter sale, making it the first OTC continuous glucose monitor (CGM). It will be open for buying in the summer of 2024.
• In January 2024 - The MiniMed™ 780G system from Medtronic plc was updated with Simplera Sync™, a disposable continuous glucose monitor (CGM) that eliminates the need for fingersticks or overtape. The new gadget delivers an improved user experience with its simple two-step insertion process, which is half the size of previous Medtronic sensors.
• In October 2023 - Simplera is a new CGM device by Medtronic for people aged two and up with diabetes. It is compact and disposable and eliminates the need for fingersticks. The FDA is currently evaluating it for approval in the United States.
• In June 2023 - I-SENS, a blood glucose device manufacturer, launched CareSens Air, a compact and lightweight continuous glucose monitoring device approved by the South Korean Ministry of Food and Drug Safety. The device can function continuously for 15 days and has a calibration mechanism for accurate readings.
• In March 2023 - The USDA-approved Eversense E3 Continuous Glucose Monitoring (CGM) System will provide real-time blood sugar (glucose) values and trends in these levels over time through a mobile app installed on a smartphone, tablet, or other compatible device.

Component – Market breakup in 3 viewpoints:

1.    Sensors
2.    Transmitters
3.    Receivers

End-User – Market breakup in 3 viewpoints:

1.    Hospitals
2.    Homecare Settings
3.    Others

Countries – Market breakup in 25 viewpoints:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina 

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    United Arab Emirates
5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Developments
•    Revenue Analysis

Company Analysis:

1.    Dexcom Inc.
2.    Ypsomed AG,
3.    Abbott Laboratories
4.    Senseonics Holdings, Inc.
5.    Nemaura Medical, Inc.
6.    Medtronic, Inc.
7.    Tandem Diabetes Care
8.    Nova Biomedical 

Report Details: